Do I need a prescription for Miconazole 2% cream?

Miconazole 2% cream is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

What are the brand names for Miconazole 2% cream?

Miconazole 2% cream is the generic name. It is available under brand names including: Acorvio 2% cream, Daktarin 2% cream, Daktarin 2% cream, Daktarin 2% cream, Daktarin 2% cream and 5 more. (Source: NHS dm+d — Actual Medicinal Products)

Miconazole 2% cream

Pharmacy only

Available from a pharmacy with pharmacist advice

Cream

Topical

Creams, ointments & gels

Anti-infective skin preparations

Active ingredients:

Miconazole

BNF classificationBrowse formulary

Where this medicine sits in the British National Formulary — the UK's standard prescribing reference

BNF 13.10.02

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

ATC D01AC02

Chemical classBrowse classes

Classification based on the molecule's chemical structure and properties

Check interactions for Miconazole

No active safety alerts

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Official medicine documents

Yellow Card

Report side effects (MHRA)

Drug safety updates

MHRA alerts for Miconazole

Source: MHRA Products DatabaseOGL 3.0

Updated 3 months ago(16 Jan 2026)

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Suspected adverse reactions reported for Miconazole

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

View EudraVigilance report

Suspected adverse reactions reported for Miconazole

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

10 branded products available

10 productsShow details

Part of the Acorvio brand family (generic: Miconazole)

10 products

Possibly available on the UK marketDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Miconazole on the MHRA register

Daktarin 2% cream

McNeil Products Ltd

Daktarin Aktiv 2% cream

McNeil Products Ltd

Acorvio 2% cream

Ferndale Pharmaceuticals Ltd

Discontinued

Daktarin 2% cream

Waymade Healthcare Plc

Discontinued

Daktarin 2% cream

Dowelhurst Ltd

Discontinued

Daktarin 2% cream

DE Pharmaceuticals

Discontinued

Daktarin 2% cream

Sigma Pharmaceuticals Plc

Discontinued

Daktarin 2% cream

Janssen-Cilag Ltd

Discontinued

Daktarin 2% cream

Mawdsley-Brooks & Company Ltd

Discontinued

Gyno-Daktarin 2% cream

Janssen-Cilag Ltd

Discontinued

Source: NHS dm+dOGL 3.0

Updated about 1 month ago(1 Mar 2026)

PriceShow details

£5.05indicative price

This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.

View full Drug Tariff

Source: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.

Therapeutically similar medicines

10 similarShow details

Econazole 1% cream

Cream

Same therapeutic group

Flutrimazole 1% cream

Cream

Same therapeutic group

Ketoconazole 1% shampoo

Other

Same therapeutic group

Bifonazole 1% cream

Cream

Same therapeutic group

Miconazole 0.16% dry powder spray

Spray

0.16%

Same therapeutic group

Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

NHS prescribing volume and spending trends

Show details

Loading prescribing data...

Clinical guidelines and formulary information

British National Formulary

Miconazole

BNF

Drug monograph — bnf.nice.org.uk

Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.

NICE clinical guidance(1)

Neonatal infection: antibiotics for prevention and treatment (NG195)

NG195

NICE guideline

Updated Mar 2024

Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.

Check stock at pharmacies and supply information

Show details

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & product information

Official product databases and supply status monitoring

Shortages info

NHS Specialist Pharmacy Service (SPS)

emc product search

Discontinuations & alternatives for Miconazole

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.

Codes for healthcare professionals and prescribing systems

Show details

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

41903211000001107

dm+d ID

41903211000001107

VTM (Virtual Therapeutic Moiety)

776782005

VMP (Virtual Medicinal Product)

41903211000001107

BNF code

13100200

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

D01AC02

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Show details

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

None known

Half-life

24 hours

Mechanism

Miconazole is an azole antifungal used to treat a variety of conditions, including those caused by Candida overgrowth.

Food interactions

None known

Human targets

7 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

50 mg

Miconazole given to healthy volunteers as a single 50 mg oral tablet produced a mean C_max of 15.1…

Half-life

24 hours

Miconazole has a terminal half-life of 24 hours.
[L14021]

Protein binding

In vitro data suggests that miconazole binds human serum albumin, however, the clinical significance of this observation is unclear.
[A188165,…

Volume of distribution

1200 mg

A 1200 mg miconazole vaginal suppository resulted in a calculated apparent volume of distribution of 95 546 L while a 100 mg vaginal cream yielded an apparent volume of distribution of 10 911L.
[A203657]…

Metabolism

Miconazole is metabolized in the liver and does not give rise to any active metabolites.
[L14021]

Elimination

Miconazole is excreted through both urine and feces; less than 1% of unchanged miconazole is recovered in urine.
[L14021]

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Vet approved

Small molecule

About this compound

Miconazole is a broad-spectrum azole antifungal with some activity against Gram-positive bacteria as well.[A203636] It is widely used to treat mucosal yeast infections, including both oral and vaginal infections; although intravenous miconazole is no longer available, a wide variety of suppositories, creams, gels, and tablet-based products are available.[L14021][L14024][L14027][L14033][L14396] Miconazole is thought to act primarily through the inhibition of fungal CYP450 14α-lanosterol demethylase activity.[A203636][A203639]

Miconazole was first synthesized in 1969 and first granted FDA approval on January 8, 1974, for sale by INSIGHT Pharmaceuticals as a topical cream.[A214523][L14021] It is currently available as a variety of prescription and over the counter products. Despite having been in clinical use for an extended period, resistance to miconazole among susceptible organisms is relatively low.[A203636]

Properties:

solid

Avg. mass: 416.13 Da

View FDA drug label

DrugBank indication

Miconazole is indicated for the local treatment of oropharyngeal candidiasis in adult patients and for the adjunctive treatment of diaper dermatitis complicated by candidiasis in immunocompetent patients aged four weeks and older.
[L14021][L14024]
Miconazole is available as both a suppository and cream for the treatment of vaginal yeast infections and the relief of associated vulvar itching and irritation.
[L14027]
Lastly, miconazole cream is effective in treating athlete's foot (tinea pedis), jock itch (tinea cruris), ringworm infections (tinea corporis),[L14033] pityriasis (formerly tinea) versicolor,[A203633] and cutaneous candidiasis.
[A203630]

Also known as(465)

1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole

1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole

Miconazol

Miconazole

Miconazolum

1.14.13.70

1.14.14.154

CYP51

Dosage forms(183)

Powder (Topical) — 1.7 g/85g

Ointment (Topical) — 20 mg/1g

Ointment (Topical) — 2.82 g/141g

Ointment (Topical) — 1.12 g/56g

Tablet (Oral) — 250 MG

Tablet (Vaginal)

Cream (Topical) — 2 mg/100mL

Cream (Topical) — 2 g/1000g

Molecular properties(18)

Drug interactions(1051)

Known interactions with other medications. Always consult a healthcare professional.

Cilostazol

Unknown severity

DB01166

The serum concentration of Cilostazol can be increased when it is combined with Miconazole.

Check this interaction

Amphotericin B

Moderate

DB00681

The therapeutic efficacy of Amphotericin B can be decreased when used in combination with Miconazole.

Check this interaction

Brexpiprazole

Moderate

DB09128

The metabolism of Brexpiprazole can be decreased when combined with Miconazole.

Check this interaction

Clopidogrel

Moderate

DB00758

The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Miconazole resulting in a loss in efficacy.

Check this interaction

Didanosine

Moderate

DB00900

Didanosine can cause a decrease in the absorption of Miconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.

Check this interaction

Eliglustat

Moderate

DB09039

The metabolism of Eliglustat can be decreased when combined with Miconazole.

Check this interaction

Everolimus

Moderate

DB01590

The metabolism of Everolimus can be decreased when combined with Miconazole.

Check this interaction

Flibanserin

Moderate

DB04908

The metabolism of Flibanserin can be decreased when combined with Miconazole.

Check this interaction

Ibrutinib

Moderate

DB09053

The metabolism of Ibrutinib can be decreased when combined with Miconazole.

Check this interaction

Ivabradine

Moderate

DB09083

The metabolism of Ivabradine can be decreased when combined with Miconazole.

Check this interaction

Ivacaftor

Moderate

DB08820

The metabolism of Ivacaftor can be decreased when combined with Miconazole.

Check this interaction

Lurasidone

Moderate

DB08815

The metabolism of Lurasidone can be decreased when combined with Miconazole.

Check this interaction

Naloxegol

Moderate

DB09049

The metabolism of Naloxegol can be decreased when combined with Miconazole.

Check this interaction

Olaparib

Moderate

DB09074

The metabolism of Olaparib can be decreased when combined with Miconazole.

Check this interaction

Ranolazine

Moderate

DB00243

The metabolism of Ranolazine can be decreased when combined with Miconazole.

Check this interaction

Sonidegib

Moderate

DB09143

The metabolism of Sonidegib can be decreased when combined with Miconazole.

Check this interaction

Avanafil

Moderate

DB06237

The metabolism of Avanafil can be decreased when combined with Miconazole.

Check this interaction

Eplerenone

Moderate

DB00700

The metabolism of Eplerenone can be decreased when combined with Miconazole.

Check this interaction

Sildenafil

Unknown severity

DB00203

The serum concentration of Sildenafil can be increased when it is combined with Miconazole.

Check this interaction

Colchicine

Moderate

DB01394

The metabolism of Colchicine can be decreased when combined with Miconazole.

Check this interaction

Fentanyl

Moderate

DB00813

The metabolism of Fentanyl can be decreased when combined with Miconazole.

Check this interaction

Iloperidone

Moderate

DB04946

The metabolism of Iloperidone can be decreased when combined with Miconazole.

Check this interaction

Retapamulin

Moderate

DB01256

The metabolism of Retapamulin can be decreased when combined with Miconazole.

Check this interaction

Tofacitinib

Moderate

DB08895

The metabolism of Tofacitinib can be decreased when combined with Miconazole.

Check this interaction

Vardenafil

Moderate

DB00862

The metabolism of Vardenafil can be decreased when combined with Miconazole.

Check this interaction

Eszopiclone

Moderate

DB00402

The metabolism of Eszopiclone can be decreased when combined with Miconazole.

Check this interaction

Zopiclone

Moderate

DB01198

The metabolism of Zopiclone can be decreased when combined with Miconazole.

Check this interaction

Lovastatin

Moderate

DB00227

The metabolism of Lovastatin can be decreased when combined with Miconazole.

Check this interaction

Alfuzosin

Moderate

DB00346

The metabolism of Alfuzosin can be decreased when combined with Miconazole.

Check this interaction

Alprazolam

Moderate

DB00404

The metabolism of Alprazolam can be decreased when combined with Miconazole.

Check this interaction

Atomoxetine

Moderate

DB00289

The metabolism of Atomoxetine can be decreased when combined with Miconazole.

Check this interaction

Sucralfate

Moderate

DB00364

Sucralfate can cause a decrease in the absorption of Miconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.

Check this interaction

Midazolam

Unknown severity

DB00683

The serum concentration of Midazolam can be increased when it is combined with Miconazole.

Check this interaction

Tacrolimus

Unknown severity

DB00864

The serum concentration of Tacrolimus can be increased when it is combined with Miconazole.

Check this interaction

Phenytoin

Unknown severity

DB00252

The serum concentration of Phenytoin can be increased when it is combined with Miconazole.

Check this interaction

Fosphenytoin

Unknown severity

DB01320

The serum concentration of Fosphenytoin can be increased when it is combined with Miconazole.

Check this interaction

Warfarin

Moderate

DB00682

The metabolism of Warfarin can be decreased when combined with Miconazole.

Check this interaction

Acenocoumarol

Moderate

DB01418

The metabolism of Acenocoumarol can be decreased when combined with Miconazole.

Check this interaction

(R)-warfarin

Moderate

DB08496

The metabolism of (R)-warfarin can be decreased when combined with Miconazole.

Check this interaction

R,S-Warfarin alcohol

Moderate

DB08735

The metabolism of R,S-Warfarin alcohol can be decreased when combined with Miconazole.

Check this interaction

S,R-Warfarin alcohol

Moderate

DB08736

The metabolism of S,R-Warfarin alcohol can be decreased when combined with Miconazole.

Check this interaction

(S)-Warfarin

Moderate

DB14055

The metabolism of (S)-Warfarin can be decreased when combined with Miconazole.

Check this interaction

Glimepiride

Unknown severity

DB00222

The serum concentration of Glimepiride can be increased when it is combined with Miconazole.

Check this interaction

Acetohexamide

Unknown severity

DB00414

The serum concentration of Acetohexamide can be increased when it is combined with Miconazole.

Check this interaction

Chlorpropamide

Unknown severity

DB00672

The serum concentration of Chlorpropamide can be increased when it is combined with Miconazole.

Check this interaction

Tolazamide

Unknown severity

DB00839

The serum concentration of Tolazamide can be increased when it is combined with Miconazole.

Check this interaction

Glyburide

Unknown severity

DB01016

The serum concentration of Glyburide can be increased when it is combined with Miconazole.

Check this interaction

Glipizide

Unknown severity

DB01067

The serum concentration of Glipizide can be increased when it is combined with Miconazole.

Check this interaction

Gliclazide

Unknown severity

DB01120

The serum concentration of Gliclazide can be increased when it is combined with Miconazole.

Check this interaction

Tolbutamide

Unknown severity

DB01124

The serum concentration of Tolbutamide can be increased when it is combined with Miconazole.

Check this interaction

Showing 50 of 1051 interactions

Toxicity & overdose

Miconazole overdose has not been reported.
[L14021]
Patients experiencing an overdose are at an increased risk of severe adverse effects such as headache, skin irritation, diarrhea, nausea, vomiting, abdominal pain, and dysgeusia. Symptomatic and supportive measures are recommended.

Miconazole has an oral LD₅₀ of 500 mg/kg in rats.MSDS

How it works

Mechanism of action

Miconazole is an azole antifungal used to treat a variety of conditions, including those caused by Candida overgrowth. Unique among the azoles, miconazole is thought to act through three main mechanisms.[A203636] The primary mechanism of action is through inhibition of the CYP450 14α-lanosterol demethylase enzyme, which results in altered ergosterol production and impaired cell membrane composition and permeability, which in turn leads to cation, phosphate, and low molecular weight protein leakage.[A203636][A203639]

In addition, miconazole inhibits fungal peroxidase and catalase while not affecting NADH oxidase activity, leading to increased production of reactive oxygen species (ROS).[A203636][A203639][A203642] Increased intracellular ROS leads to downstream pleiotropic effects and eventual apoptosis.[A203636]

Lastly, likely as a result of lanosterol demethylation inhibition, miconazole causes a rise in intracellular levels of farnesol. This molecule participates in quorum sensing in Candida, preventing the transition from yeast to mycelial forms and thereby the formation of biofilms, which are more resistant to antibiotics.[A203645][A203648] In addition, farnesol is an inhibitor of drug efflux ABC transporters, namely Candida CaCdr1p and CaCdr2p, which may additionally contribute to increased effectiveness of azole drugs.[A203648]

Pharmacodynamics

Miconazole is an azole antifungal that functions primarily through inhibition of a specific demethylase within the CYP450 complex.[A203636] As miconazole is typically applied topically and is minimally absorbed into the systemic circulation following application, the majority of patient reactions are limited to hypersensitivity and cases of anaphylaxis.[L14021] Patients using intravaginal miconazole products are advised not to rely on contraceptives to prevent pregnancy and sexually transmitted infections, as well as not to use tampons concurrently.[L14027]

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Absorption

Miconazole given to healthy volunteers as a single 50 mg oral tablet produced a mean C_max of 15.1 ± 16.2 mcg/mL, a mean AUC_0-24 of 55.2 ± 35.1 mcg\*h/mL, and a median T_max of 7 hours (range 2.0-24.1). In these patients measurable plasma concentrations ranged from 0.5 to 0.83 mcg/mL.
[L14021]

Topical miconazole is absorbed poorly into the systemic circulation.
[A203636]
In pediatric patients aged 1-21 months given multiple topical applications of miconazole ointment for seven days, the plasma miconazole concentration was less than 0.5 ng/mL in 88% of the patients, with the remaining patients having a concentration of 0.57 and 0.58 ng/mL, respectively.
[L14024]
Similarly, patients. administered with a vaginal 1200 mg ovule had a mean C_max of 10.71 ng/mL, mean T_max of 18.4 hours, and mean AUC_0-96 of 477.3 ng\*h/mL.
[A203657]

Half-life

Miconazole has a terminal half-life of 24 hours.
[L14021]

Protein binding

In vitro data suggests that miconazole binds human serum albumin, however, the clinical significance of this observation is unclear.
[A188165][A214463]

Volume of distribution

Metabolism

Miconazole is metabolized in the liver and does not give rise to any active metabolites.
[L14021]

Route of elimination

Miconazole is excreted through both urine and feces; less than 1% of unchanged miconazole is recovered in urine.
[L14021]

Drug targets(7)

Proteins and enzymes this drug interacts with in the body

Nitric oxide synthase 3

BE0000263

NOS3

inhibitor

Specific functionactin monomer binding

Cellular location

Cell membrane

General function & pharmacology

Produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a cGMP-mediated signal transduction pathway .
PMID:1378832
NO mediates vascular endothelial growth factor (VEGF)-induced angiogenesis in coronary vessels and promotes blood clotting through the activation of platelets

Nitric oxide synthase, inducible

BE0000005

NOS2

inhibitor

Specific functionarginine binding

Cellular location

Cytoplasm, cytosol

General function & pharmacology

Produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body .
PMID:7504305 PMID:7531687 PMID:7544004 PMID:7682706

In macrophages, NO mediates tumoricidal and bactericidal actions. Also has nitrosylase activity and mediates cysteine S-nitrosylation of cytoplasmic target proteins such PTGS2/COX2 (By similarity). As component of the iNOS-S100A8/9 transnitrosylase complex involved in the selective inflammatory stimulus-dependent S-nitrosylation of GAPDH on 'Cys-247' implicated in regulation of the GAIT complex activity and probably multiple targets including ANXA5, EZR, MSN and VIM .
PMID:25417112
Involved in inflammation, enhances the synthesis of pro-inflammatory mediators such as IL6 and IL8 PMID:19688109

Nuclear receptor subfamily 1 group I member 2

BE0000956

NR1I2

partial agonist

Specific functionDNA-binding transcription activator activity, RNA polymerase II-specific

Cellular location

Nucleus

General function & pharmacology

Nuclear receptor that binds and is activated by variety of endogenous and xenobiotic compounds. Transcription factor that activates the transcription of multiple genes involved in the metabolism and secretion of potentially harmful xenobiotics, drugs and endogenous compounds. Activated by the antibiotic rifampicin and various plant metabolites, such as hyperforin, guggulipid, colupulone, and isoflavones.

Response to specific ligands is species-specific. Activated by naturally occurring steroids, such as pregnenolone and progesterone. Binds to a response element in the promoters of the CYP3A4 and ABCB1/MDR1 genes

Small conductance calcium-activated potassium channel protein 3

BE0004906

KCNN3

inhibitor

Specific functioncalmodulin binding

Cellular location

Cell membrane

General function & pharmacology

Small conductance calcium-activated potassium channel that mediates the voltage-independent transmembrane transfer of potassium across the cell membrane through a constitutive interaction with calmodulin which binds the intracellular calcium allowing its opening .
PMID:12808432 PMID:20562108 PMID:31155282 PMID:36502918

The current is characterized by a voltage-independent activation, an intracellular calcium concentration increase-dependent activation and a single-channel conductance of 10 picosiemens .
PMID:12808432 PMID:20562108 PMID:31155282 PMID:36502918

Also presents an inwardly rectifying current, thus reducing its already small outward conductance of potassium ions, which is particularly the case when the membrane potential displays positive values, above + 20 mV .
PMID:12808432
Activation is followed by membrane hyperpolarization. Thought to regulate neuronal excitability by contributing to the slow component of synaptic afterhyperpolarization (By similarity)

Voltage-gated potassium channel subunit beta-2

BE0009847

KCNAB2

inhibitor

Specific functionaldo-keto reductase (NADPH) activity

Cellular location

Cytoplasm

General function & pharmacology

Regulatory subunit of the voltage-gated potassium (Kv) Shaker channels composed of pore-forming and potassium-conducting alpha subunits and of regulatory beta subunits .
PMID:11825900 PMID:7649300
The beta-2/KCNAB2 cytoplasmic subunit promotes potassium channel closure via a mechanism that does not involve physical obstruction of the channel pore .
PMID:11825900 PMID:7649300
Promotes the inactivation of Kv1.4/KCNA4 and Kv1.5/KCNA5 alpha subunit-containing channels .
PMID:11825900 PMID:7649300
Displays nicotinamide adenine dinucleotide phosphate (NADPH)-dependent aldoketoreductase activity by catalyzing the NADPH-dependent reduction of a wide range of aldehyde and ketone substrates (By similarity). Substrate specificity includes methylglyoxal, 9,10-phenanthrenequinone, prostaglandin J2, 4-nitrobenzaldehyde, 4-nitroacetophenone and 4-oxo-trans-2-nonenal (in vitro, no physiological substrate identified yet) (By similarity). The binding of oxidized and reduced nucleotide alters Kv channel gating and may contribute to dynamic fine tuning of cell excitability (By similarity).

Contributes to the regulation of nerve signaling, and prevents neuronal hyperexcitability (By similarity)

Metabolizing enzymes(11)

Enzymes involved in drug metabolism — important for understanding drug interactions

Enzyme activity key

substrate

inhibitor

inducer

CYP2C9Cytochrome P450 2C9

inhibitor

CYP2C19Cytochrome P450 2C19

inhibitor

CYP2A6Cytochrome P450 2A6

inhibitor

CYP2E1Cytochrome P450 2E1

inhibitor

CYP3A4Cytochrome P450 3A4

inhibitor

CYP2B6Cytochrome P450 2B6

inhibitor

CYP2D6Cytochrome P450 2D6

inhibitor

CYP2C8Cytochrome P450 2C8

inhibitor

CYP11B1Cytochrome P450 11B1, mitochondrial

inhibitor

CYP51A1Lanosterol 14-alpha demethylase

inhibitor

CYP19A1Aromatase

inhibitor

Transporters(1)

Proteins that transport this drug across cell membranes

ATP-dependent translocase ABCB1

BE0001032

ABCB1

inhibitor

Specific functionABC-type xenobiotic transporter activity

Cellular location

Cell membrane

General function & pharmacology

Translocates drugs and phospholipids across the membrane .
PMID:2897240 PMID:35970996 PMID:8898203 PMID:9038218 PMID:35507548

Catalyzes the flop of phospholipids from the cytoplasmic to the exoplasmic leaflet of the apical membrane. Participates mainly to the flop of phosphatidylcholine, phosphatidylethanolamine, beta-D-glucosylceramides and sphingomyelins .
PMID:8898203
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells PMID:2897240 PMID:35970996 PMID:9038218

Carriers(1)

Proteins that carry this drug through the body

Albumin

BE0000530

ALB

binder

Specific functionantioxidant activity

Cellular location

Secreted

General function & pharmacology

Binds water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs (Probable). Its main function is the regulation of the colloidal osmotic pressure of blood (Probable). Major zinc transporter in plasma, typically binds about 80% of all plasma zinc .
PMID:19021548
Major calcium and magnesium transporter in plasma, binds approximately 45% of circulating calcium and magnesium in plasma (By similarity).

Potentially has more than two calcium-binding sites and might additionally bind calcium in a non-specific manner (By similarity). The shared binding site between zinc and calcium at residue Asp-273 suggests a crosstalk between zinc and calcium transport in the blood (By similarity). The rank order of affinity is zinc > calcium > magnesium (By similarity).

Binds to the bacterial siderophore enterobactin and inhibits enterobactin-mediated iron uptake of E.coli from ferric transferrin, and may thereby limit the utilization of iron and growth of enteric bacteria such as E.coli .
PMID:6234017
Does not prevent iron uptake by the bacterial siderophore aerobactin PMID:6234017

Scientific references(12)

Taudorf E.H., Jemec G.B.E., Hay R.J., Saunte D.M.L.

Cutaneous candidiasis - an evidence-based review of topical and systemic treatments to inform clinical practice.

Journal European Academy Dermatology Venereol

2019 Oct33(10):1863-1873. doi: 10.1111/jdv.15782. Epub 2019 Jul 30

PMID: 31287594 DOI: 10.1111/jdv.15782

Tanenbaum L., Anderson C., Rosenberg M.J., Akers W.

1% Sulconazole Cream v 2% Miconazole Cream in the Treatment of Tinea Versicolor.

Archives of Dermatology

1984120(2):216. doi: 10.1001/archderm.1984.01650380076015

PMID: 6364994 DOI: 10.1001/archderm.1984.01650380076015

Pierard G.E., Hermanns-Le T., Delvenne P., Pierard-Franchimont C.

Miconazole, a pharmacological barrier to skin fungal infections.

Expert Opinion on Pharmacotherapy

2012 Jun13(8):1187-94. doi: 10.1517/14656566.2012.687047. Epub 2012 May 8

PMID: 22568580 DOI: 10.1517/14656566.2012.687047

De Nollin S., Borgers M.

An ultrastructural and cytochemical study of Candida albicans after in vitro treatment with imidazoles.

Mykosen

1976 Sep19(9):317-28. doi: 10.1111/j.1439-0507.1976.tb01469.x

PMID: 185515 DOI: 10.1111/j.1439-0507.1976.tb01469.x

Kobayashi D., Kondo K., Uehara N., Otokozawa S., Tsuji N., Yagihashi A., Watanabe N.

Endogenous reactive oxygen species is an important mediator of miconazole antifungal effect.

Antimicrob Agents Chemother

2002 Oct46(10):3113-7. doi: 10.1128/aac.46.10.3113-3117.2002

PMID: 12234832 DOI: 10.1128/aac.46.10.3113-3117.2002

Hornby J.M., Nickerson K.W.

Enhanced production of farnesol by Candida albicans treated with four azoles.

Antimicrob Agents Chemother

2004 Jun48(6):2305-7. doi: 10.1128/AAC.48.6.2305-2307.2004

PMID: 15155241 DOI: 10.1128/AAC.48.6.2305-2307.2004

Sharma M., Prasad R.

The quorum-sensing molecule farnesol is a modulator of drug efflux mediated by ABC multidrug transporters and synergizes with drugs in Candida albicans.

Antimicrob Agents Chemother

2011 Oct55(10):4834-43. doi: 10.1128/AAC.00344-11. Epub 2011 Jul 18

PMID: 21768514 DOI: 10.1128/AAC.00344-11

Thevissen K., Ayscough K.R., Aerts A.M., Du W., De Brucker K., Meert E.M., Ausma J., Borgers M., Cammue B.P., Francois I.E.

Miconazole induces changes in actin cytoskeleton prior to reactive oxygen species induction in yeast.

Journal of Biological Chemistry

2007 Jul 27282(30):21592-7. doi: 10.1074/jbc.M608505200. Epub 2007 Jun 6

PMID: 17553796 DOI: 10.1074/jbc.M608505200

Stevens R.E., Konsil J., Verrill S.S., Roy P., Desai P.B., Upmalis D.H., Cone F.L.

Bioavailability study of a 1200 mg miconazole nitrate vaginal ovule in healthy female adults.

Journal of Clinical Pharmacology

2002 Jan42(1):52-60. doi: 10.1177/0091270002042001006

PMID: 11808824 DOI: 10.1177/0091270002042001006

Schafer-Korting M., Korting H.C., Rittler W., Obermuller W.

Influence of serum protein binding on the in vitro activity of anti-fungal agents.

Infection

1995 Sep-Oct23(5):292-7. doi: 10.1007/bf01716289

PMID: 8557388 DOI: 10.1007/bf01716289

Hu Z., Zhang J., Cheng X.

Antifungal efficiency of miconazole and econazole and the interaction with transport protein: a comparative study.

Pharmacy Biological

2015 Feb53(2):251-61. doi: 10.3109/13880209.2014.914232. Epub 2014 Nov 7

PMID: 25376919 DOI: 10.3109/13880209.2014.914232

Godefroi E.F., Heeres J., Van Cutsem J., Janssen P.A.

The preparation and antimycotic properties of derivatives of 1-phenethylimidazole.

Journal of Medicinal Chemistry

1969 Sep12(5):784-91. doi: 10.1021/jm00305a014

PMID: 4897900 DOI: 10.1021/jm00305a014

ATC classification(8 codes)

ATC A07AC01

ATC J02AB01

ATC D01AC52

ATC G01AF20

ATC A01AB09

ATC D01AC02

ATC S02AA13

ATC G01AF04

Affected organisms(1)

Fungi, yeast and protozoans

International brands(10)

Salt forms(1)

Miconazole nitrate(DBSALT001242)

Experimental properties(1)

External resources(3)

RxList PDRhealth Drugs.com

Commercial products(731)

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Miconazole

DB01110

CAS number

22916-47-8

UNII (FDA)

7NNO0D7S5M

InChI Key (molecular fingerprint)

BYBLEWFAAKGYCD-UHFFFAOYSA-N

Additional database identifiers

Drugs Product Database (DPD)

2373

Drugs Product Database (DPD)

11249

ChEBI

82892

PubChem Compound

4189

PubChem Substance

46506017

KEGG Compound

C08070

KEGG Drug

D00882

ChemSpider

4044

BindingDB

31772

PharmGKB

PA450494

Therapeutic Targets Database

DAP000154

IUPHAR

2449

Guide to Pharmacology

2449

Wikipedia

Miconazole

ChEMBL

CHEMBL91

RxCUI

6932

GenBank Gene Database

X13296

GenBank Protein Database

578119

UniProtKB

P10613

UniProt Accession

CP51_CANAL

HUGO Gene Nomenclature Committee (HGNC)

HGNC:7876

GenAtlas

NOS3

GeneCards

NOS3

GenBank Gene Database

M93718

GenBank Protein Database

189212

Guide to Pharmacology

1249

UniProtKB

P29474

UniProt Accession

NOS3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:7873

GenAtlas

NOS2A

GeneCards

NOS2

GenBank Gene Database

L09210

GenBank Protein Database

292242

Guide to Pharmacology

1250

UniProtKB

P35228

UniProt Accession

NOS2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:7968

GenAtlas

NR1I2

GeneCards

NR1I2

GenBank Gene Database

AF061056

GenBank Protein Database

3511138

IUPHAR

606

Guide to Pharmacology

606

UniProtKB

O75469

UniProt Accession

NR1I2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6284

GenAtlas

KCNMA1

GeneCards

KCNMA1

GenBank Gene Database

U13913

GenBank Protein Database

537439

IUPHAR

380

Guide to Pharmacology

380

UniProtKB

Q12791

UniProt Accession

KCMA1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6285

GeneCards

KCNMB1

GenBank Gene Database

U25138

GenBank Protein Database

1326067

UniProtKB

Q16558

UniProt Accession

KCMB1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6286

GenAtlas

KCNMB2

GeneCards

KCNMB2

GenBank Gene Database

AF099137

UniProtKB

Q9Y691

UniProt Accession

KCMB2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6287

GeneCards

KCNMB3

GenBank Gene Database

AF139471

GenBank Protein Database

5880671

UniProtKB

Q9NPA1

UniProt Accession

KCMB3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6289

GeneCards

KCNMB4

GenBank Gene Database

AF160967

GenBank Protein Database

7799988

UniProtKB

Q86W47

UniProt Accession

KCMB4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6293

GenAtlas

KCNN4

GeneCards

KCNN4

GenBank Gene Database

AF000972

GenBank Protein Database

2584866

IUPHAR

384

Guide to Pharmacology

384

UniProtKB

O15554

UniProt Accession

KCNN4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6290

GeneCards

KCNN1

GenBank Gene Database

U69883

GenBank Protein Database

1575661

Guide to Pharmacology

381

UniProtKB

Q92952

UniProt Accession

KCNN1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6291

GeneCards

KCNN2

GenBank Gene Database

AF239613

GenBank Protein Database

10334701

Guide to Pharmacology

382

UniProtKB

Q9H2S1

UniProt Accession

KCNN2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6292

GeneCards

KCNN3

GenBank Gene Database

AF031815

GenBank Protein Database

3309531

Guide to Pharmacology

383

UniProtKB

Q9UGI6

UniProt Accession

KCNN3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6237

GeneCards

KCND1

Guide to Pharmacology

552

UniProtKB

Q9NSA2

UniProt Accession

KCND1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6238

GeneCards

KCND2

GenBank Gene Database

AF121104

GenBank Protein Database

4530478

UniProtKB

Q9NZV8

UniProt Accession

KCND2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6239

GeneCards

KCND3

GenBank Gene Database

AF048712

GenBank Protein Database

2935434

UniProtKB

Q9UK17

UniProt Accession

KCND3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6300

GeneCards

KCNS1

UniProtKB

Q96KK3

UniProt Accession

KCNS1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6302

GeneCards

KCNS3

UniProtKB

Q9BQ31

UniProt Accession

KCNS3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6218

GenAtlas

KCNA1

GeneCards

KCNA1

GenBank Gene Database

L02750

GenBank Protein Database

186663

IUPHAR

538

Guide to Pharmacology

538

UniProtKB

Q09470

UniProt Accession

KCNA1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6219

GeneCards

KCNA10

Guide to Pharmacology

545

UniProtKB

Q16322

UniProt Accession

KCA10_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6220

GeneCards

KCNA2

Guide to Pharmacology

539

UniProtKB

P16389

UniProt Accession

KCNA2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6221

GeneCards

KCNA3

Guide to Pharmacology

540

UniProtKB

P22001

UniProt Accession

KCNA3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6222

GeneCards

KCNA4

UniProtKB

P22459

UniProt Accession

KCNA4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6224

GeneCards

KCNA5

Guide to Pharmacology

542

UniProtKB

P22460

UniProt Accession

KCNA5_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6225

GeneCards

KCNA6

Guide to Pharmacology

543

UniProtKB

P17658

UniProt Accession

KCNA6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6231

GeneCards

KCNB1

Guide to Pharmacology

546

UniProtKB

Q14721

UniProt Accession

KCNB1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6232

GeneCards

KCNB2

Guide to Pharmacology

547

UniProtKB

Q92953

UniProt Accession

KCNB2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6240

GenAtlas

KCNE1

GeneCards

KCNE1

GenBank Gene Database

M26685

GenBank Protein Database

386838

UniProtKB

P15382

UniProt Accession

KCNE1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6242

GeneCards

KCNE2

UniProtKB

Q9Y6J6

UniProt Accession

KCNE2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6243

GeneCards

KCNE3

UniProtKB

Q9Y6H6

UniProt Accession

KCNE3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6244

GeneCards

KCNE4

UniProtKB

Q8WWG9

UniProt Accession

KCNE4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6241

GeneCards

KCNE5

UniProtKB

Q9UJ90

UniProt Accession

KCNE5_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6294

GenAtlas

KCNQ1

GeneCards

KCNQ1

GenBank Gene Database

AF000571

GenBank Protein Database

2465531

IUPHAR

560

Guide to Pharmacology

560

UniProtKB

P51787

UniProt Accession

KCNQ1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6296

GenAtlas

KCNQ2

GeneCards

KCNQ2

GenBank Gene Database

D82346

GenBank Protein Database

1841342

IUPHAR

561

Guide to Pharmacology

561

UniProtKB

O43526

UniProt Accession

KCNQ2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6297

GenAtlas

KCNQ3

GeneCards

KCNQ3

GenBank Gene Database

AF071491

IUPHAR

562

Guide to Pharmacology

562

UniProtKB

O43525

UniProt Accession

KCNQ3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6298

GenAtlas

KCNQ4

GeneCards

KCNQ4

GenBank Gene Database

AF105202

IUPHAR

563

Guide to Pharmacology

563

UniProtKB

P56696

UniProt Accession

KCNQ4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6299

GenAtlas

KCNQ5

GeneCards

KCNQ5

GenBank Gene Database

AF249278

IUPHAR

564

Guide to Pharmacology

564

UniProtKB

Q9NR82

UniProt Accession

KCNQ5_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:18861

GeneCards

KCNV1

UniProtKB

Q6PIU1

UniProt Accession

KCNV1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:19698

GeneCards

KCNV2

UniProtKB

Q8TDN2

UniProt Accession

KCNV2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6250

GeneCards

KCNH1

Guide to Pharmacology

570

UniProtKB

O95259

UniProt Accession

KCNH1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6253

GeneCards

KCNH4

UniProtKB

Q9UQ05

UniProt Accession

KCNH4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6254

GeneCards

KCNH5

Guide to Pharmacology

571

UniProtKB

Q8NCM2

UniProt Accession

KCNH5_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:18864

GeneCards

KCNH8

Guide to Pharmacology

575

UniProtKB

Q96L42

UniProt Accession

KCNH8_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6251

GenAtlas

KCNH2

GeneCards

KCNH2

GenBank Gene Database

U04270

GenBank Protein Database

487738

IUPHAR

572

Guide to Pharmacology

572

UniProtKB

Q12809

UniProt Accession

KCNH2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6252

GeneCards

KCNH3

Guide to Pharmacology

576

UniProtKB

Q9ULD8

UniProt Accession

KCNH3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:18862

GenAtlas

KCNH6

GeneCards

KCNH6

GenBank Gene Database

AF311913

GenBank Protein Database

11878259

IUPHAR

573

Guide to Pharmacology

573

UniProtKB

Q9H252

UniProt Accession

KCNH6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:18863

GenAtlas

KCNH7

GeneCards

KCNH7

GenBank Gene Database

AF032897

GenBank Protein Database

4104136

IUPHAR

574

UniProtKB

Q9NS40

UniProt Accession

KCNH7_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6233

GeneCards

KCNC1

UniProtKB

P48547

UniProt Accession

KCNC1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6234

GeneCards

KCNC2

Guide to Pharmacology

549

UniProtKB

Q96PR1

UniProt Accession

KCNC2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6235

GeneCards

KCNC3

UniProtKB

Q14003

UniProt Accession

KCNC3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6236

GenAtlas

KCNC4

GeneCards

KCNC4

GenBank Gene Database

AL137790

IUPHAR

551

UniProtKB

Q03721

UniProt Accession

KCNC4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6246

GeneCards

KCNF1

UniProtKB

Q9H3M0

UniProt Accession

KCNF1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6248

GeneCards

KCNG1

UniProtKB

Q9UIX4

UniProt Accession

KCNG1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6249

GeneCards

KCNG2

UniProtKB

Q9UJ96

UniProt Accession

KCNG2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:18306

GeneCards

KCNG3

UniProtKB

Q8TAE7

UniProt Accession

KCNG3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:19697

GeneCards

KCNG4

UniProtKB

Q8TDN1

UniProt Accession

KCNG4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6228

GeneCards

KCNAB1

UniProtKB

Q14722

UniProt Accession

KCAB1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6229

GeneCards

KCNAB2

UniProtKB

Q13303

UniProt Accession

KCAB2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6258

GenAtlas

KCNJ12

GeneCards

KCNJ12

GenBank Gene Database

L36069

GenBank Protein Database

567019

IUPHAR

431

Guide to Pharmacology

431

UniProtKB

Q14500

UniProt Accession

KCJ12_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6260

GeneCards

KCNJ14

Guide to Pharmacology

433

UniProtKB

Q9UNX9

UniProt Accession

KCJ14_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6263

GeneCards

KCNJ2

UniProtKB

P63252

UniProt Accession

KCNJ2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6265

GeneCards

KCNJ4

Guide to Pharmacology

432

UniProtKB

P48050

UniProt Accession

KCNJ4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1390

GenAtlas

CACNA1C

GeneCards

CACNA1C

GenBank Gene Database

M92270

IUPHAR

529

Guide to Pharmacology

529

UniProtKB

Q13936

UniProt Accession

CAC1C_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1391

GenAtlas

CACNA1D

GeneCards

CACNA1D

GenBank Gene Database

M76558

GenBank Protein Database

179764

IUPHAR

530

Guide to Pharmacology

530

UniProtKB

Q01668

UniProt Accession

CAC1D_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1393

GenAtlas

CACNA1F

GeneCards

CACNA1F

GenBank Gene Database

AJ006216

GenBank Protein Database

3183953

IUPHAR

531

Guide to Pharmacology

531

UniProtKB

O60840

UniProt Accession

CAC1F_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1397

GenAtlas

CACNA1S

GeneCards

CACNA1S

GenBank Gene Database

U30707

GenBank Protein Database

1698403

IUPHAR

528

Guide to Pharmacology

528

UniProtKB

Q13698

UniProt Accession

CAC1S_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1401

GenAtlas

CACNB1

GeneCards

CACNB1

GenBank Gene Database

M92303

GenBank Protein Database

179806

UniProtKB

Q02641

UniProt Accession

CACB1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1402

GenAtlas

CACNB2

GeneCards

CACNB2

GenBank Gene Database

S60415

GenBank Protein Database

300417

UniProtKB

Q08289

UniProt Accession

CACB2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1403

GenAtlas

CACNB3

GeneCards

CACNB3

GenBank Gene Database

X76555

GenBank Protein Database

435135

UniProtKB

P54284

UniProt Accession

CACB3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1404

GenAtlas

CACNB4

GeneCards

CACNB4

GenBank Gene Database

U95020

GenBank Protein Database

2058727

UniProtKB

O00305

UniProt Accession

CACB4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2623

GenAtlas

CYP2C9

GeneCards

CYP2C9

GenBank Gene Database

AY341248

Guide to Pharmacology

1326

UniProtKB

P11712

UniProt Accession

CP2C9_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2621

GeneCards

CYP2C19

GenBank Gene Database

M61854

GenBank Protein Database

181344

Guide to Pharmacology

1328

UniProtKB

P33261

UniProt Accession

CP2CJ_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2610

GenAtlas

CYP2A6

GeneCards

CYP2A6

GenBank Gene Database

X13897

Guide to Pharmacology

1321

UniProtKB

P11509

UniProt Accession

CP2A6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2631

GeneCards

CYP2E1

GenBank Gene Database

J02625

GenBank Protein Database

181360

Guide to Pharmacology

1330

UniProtKB

P05181

UniProt Accession

CP2E1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2637

GenAtlas

CYP3A4

GeneCards

CYP3A4

GenBank Gene Database

M18907

Guide to Pharmacology

1337

UniProtKB

P08684

UniProt Accession

CP3A4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2615

GeneCards

CYP2B6

GenBank Gene Database

M29874

GenBank Protein Database

181296

Guide to Pharmacology

1324

UniProtKB

P20813

UniProt Accession

CP2B6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2625

GenAtlas

CYP2D6

GeneCards

CYP2D6

GenBank Gene Database

M20403

GenBank Protein Database

181350

Guide to Pharmacology

1329

UniProtKB

P10635

UniProt Accession

CP2D6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2622

GenAtlas

CYP2C8

GeneCards

CYP2C8

GenBank Gene Database

M17397

Guide to Pharmacology

1325

UniProtKB

P10632

UniProt Accession

CP2C8_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2591

GenAtlas

CYP11B1

GeneCards

CYP11B1

GenBank Gene Database

M32879

GenBank Protein Database

181333

Guide to Pharmacology

1359

UniProtKB

P15538

UniProt Accession

C11B1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2649

GenAtlas

CYP51A1

GeneCards

CYP51A1

GenBank Gene Database

U23942

GenBank Protein Database

1698396

Guide to Pharmacology

1374

UniProtKB

Q16850

UniProt Accession

CP51A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2594

GenAtlas

CYP19A1

GeneCards

CYP19A1

GenBank Gene Database

M22246

GenBank Protein Database

179002

Guide to Pharmacology

1362

UniProtKB

P11511

UniProt Accession

CP19A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:399

GenAtlas

ALB

GeneCards

ALB

GenBank Gene Database

V00494

GenBank Protein Database

28590

UniProtKB

P02768

UniProt Accession

ALBU_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:40

GenAtlas

ABCB1

GeneCards

ABCB1

GenBank Gene Database

M14758

GenBank Protein Database

307180

Guide to Pharmacology

768

UniProtKB

P08183

UniProt Accession

MDR1_HUMAN

International reference pricing

18 formulations

Reference pricing from DrugBank. Prices are indicative and may not reflect current UK costs.

From $0.04/g

To $284.34/tube

Lotrimin af 2% liquid spray

$0.04/g

Micatin 2% aerosol spray

$0.05/g

Antifungal 2% cream

$0.10/g

Miconazole 7 cream

$0.15/g

CVS Pharmacy miconazole 7 cream

$0.18/g

Source: DrugBank. Used under CC BY-NC 4.0 academic licence for non-commercial purposes.

Patent information

1 active patent, 5 expired

8147852

United States

Approved 3 Apr 2012 · Expires 30 Mar 2028

1y 12m

6916485

United States

Approved 12 Jul 2005 · Expires 11 Sept 2022

Expired

7651698

United States

Approved 26 Jan 2010 · Expires 11 Sept 2022

Expired

8518442

United States

Approved 27 Aug 2013 · Expires 11 Sept 2022

Expired

6153635

United States

Approved 28 Nov 2000 · Expires 28 Nov 2020

Expired

The earliest active patent expires March 2028. Generic versions may become available after this date.

Source: DrugBank · CC BY-NC 4.0. Patent data sourced from national patent offices. Expiry dates may not reflect extensions, regulatory exclusivity periods, or legal challenges.

DrugBank citations

If you use DrugBank data in your research, please cite the following publications:

Knox C., Wilson M., Klinger C.M., et al

DrugBank 6.

0: the DrugBank Knowledgebase for 2024

Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275

PMID: 37953279

Wishart D.S., Feunang Y.D., Guo A.C., et al

DrugBank 5.

0: a major update to the DrugBank database for 2018

Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082

PMID: 29126136

Show earlier publications

Law V., Knox C., Djoumbou Y., et al

DrugBank 4.

0: shedding new light on drug metabolism

Nucleic Acids Res. 2014 Jan 142(1):D1091-7

PMID: 24203711

Knox C., Law V., Jewison T., et al

DrugBank 3.

0: a comprehensive resource for 'omics' research on drugs

Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41

PMID: 21059682

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a knowledgebase for drugs, drug actions and drug targets.

Nucleic Acids Research

2008 Jan36(Database issue):D901-6

PMID: 18048412

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a comprehensive resource for in silico drug discovery and exploration.

Nucleic Acids Research

2006 Jan 134(Database issue):D668-72

PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated 26 days ago(8 Mar 2026)

Back to medicines

Miconazole 2% cream

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

British National Formulary

NICE clinical guidance(1)

Pharmacy stock checkers

Supply & product information

NHS UK identifiers

International identifiers

Browse tools

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Volume of distribution

Metabolism

Elimination

Clinical essentials

Pharmacology

Deep science
20

Chemical identifiers

Miconazole

Additional database identifiers

International reference pricing

Patent information

DrugBank citations

Miconazole 2% cream

Safety & regulatory

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

NHS reimbursement price

Medicines like this

Prescribing statistics

Guidance (NICE / BNF)

British National Formulary

NICE clinical guidance(1)

Availability, stocks & shortages

Pharmacy stock checkers

Supply & product information

Professional identifiers

NHS UK identifiers

International identifiers

Browse tools

Clinical trials

DrugBank data

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Volume of distribution

Metabolism

Elimination

Clinical essentials

Pharmacology

Deep science20

Chemical identifiers

Miconazole

Additional database identifiers

International reference pricing

Patent information

DrugBank citations

Deep science
20